Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis

Open access
Fischbach, Felix, Richter, Johanna, Pfeffer, Lena Kristina, Fehse, Boris, Berger, Susanna Carolina, Reinhardt, Stefanie, Kuhle, Jens, Badbaran, Anita, Rathje, Kristin, Gagelmann, Nico, Borie, Dominic, Seibel, Johan, Ayuk, Francis, Friese, Manuel A., Heesen, Christoph, Kröger, Nicolaus · 2024 · Med

Abstract

BACKGROUND: Progressive multiple sclerosis (MS) is characterized by compartmentalized smoldering neuroinflammation caused by the proliferation of immune cells residing in the central nervous system (CNS), including B cells. Although inflammatory activity can be prevented by immunomodulatory therapies during early disease, such therapies typically fail to halt disease progression. CD19 chimeric antigen receptor (CAR)-T cell therapies have revolutionized the field of hematologic malignancies. Although generally considered efficacious, serious adverse events associated with CAR-T cell therapies such as immune effector cell-associated neurotoxicity syndrome (ICANS) have been observed. Successful use of CD19 CAR-T cells in rheumatic diseases like systemic lupus erythematosus and neuroimmunological diseases like myasthenia gravis have recently been observed, suggesting possible application in other autoimmune diseases. METHODS: Here, we report the first individual treatment with a fully human CD19 CAR-T cell therapy (KYV-101) in two patients with progressive MS. FINDINGS: CD19 CAR-T cell administration resulted in acceptable safety profiles for both patients. No ICANS was observed despite detection of CD19 CAR-T cells in the cerebrospinal fluid. In case 1, intrathecal antibody production in the cerebrospinal fluid decreased notably after CAR-T cell infusion and was sustained through day 64. CONCLUSIONS: target cells in the CNS. Larger clinical studies assessing CD19 CAR-T cells in MS are warranted. FUNDING: Both individual treatments as well the generated data were not based on external funding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.medj.2024.03.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 192

Metadata

Authors
Fischbach, F., Richter, J., Pfeffer, L. K., Fehse, B., Berger, S. C., Reinhardt, S., Kuhle, J., Badbaran, A., Rathje, K., Gagelmann, N., Borie, D., Seibel, J., Ayuk, F., Friese, M. A., Heesen, C., & Kröger, N.
Venue
Med
Publisher
Elsevier BV
Published
2024-06
Volume
5
Issue
6
Pages
550-558.e2
ISSN
2666-6340 (ISSN-L)
OpenAlex
W4393321268
Cited by
192
References
3
FWCI
29.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. https://app.cochat.ai/papers/10.1016/j.medj.2024.03.002
The paper
Fischbach, F., Richter, J., Pfeffer, L. K., Fehse, B., Berger, S. C., Reinhardt, S., Kuhle, J., Badbaran, A., Rathje, K., Gagelmann, N., Borie, D., Seibel, J., Ayuk, F., Friese, M. A., Heesen, C., & Kröger, N. (2024). CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. https://doi.org/10.1016/j.medj.2024.03.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.